Avidity Biosciences/$RNA
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Avidity Biosciences
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Ticker
$RNA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
391
ISIN
US05370A1088
Website
RNA Metrics
BasicAdvanced
$3.5B
-
-$3.03
0.99
-
Price and volume
Market cap
$3.5B
Beta
0.99
52-week high
$49.81
52-week low
$21.51
Average daily volume
1.3M
Financial strength
Current ratio
16.909
Quick ratio
16.691
Long term debt to equity
0.157
Total debt to equity
0.45
Profitability
EBITDA (TTM)
-430.346
Gross margin (TTM)
-3,666.67%
Net profit margin (TTM)
-4,135.99%
Operating margin (TTM)
-4,853.43%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-22.47%
Return on equity (TTM)
-34.19%
Valuation
Price to revenue (TTM)
401.537
Price to book
2.66
Price to tangible book (TTM)
2.66
Price to free cash flow (TTM)
-9.814
Free cash flow yield (TTM)
-10.19%
Free cash flow per share (TTM)
-299.15%
Growth
Revenue change (TTM)
-17.87%
Earnings per share change (TTM)
2.22%
3-year revenue growth (CAGR)
1.98%
3-year earnings per share growth (CAGR)
1.32%
What the Analysts think about RNA
Analyst ratings (Buy, Hold, Sell) for Avidity Biosciences stock.
Bulls say / Bears say
Avidity Biosciences expanded its collaboration with Bristol Myers Squibb in November 2023, focusing on up to five cardiovascular targets, with a $100 million upfront payment and potential milestone payments up to $2.2 billion. (biospace.com)
The company reported a significant increase in cash, cash equivalents, and marketable securities, totaling $1.5 billion as of December 31, 2024, up from $595.4 million the previous year, indicating strong financial health. (biospace.com)
Avidity's lead product candidate, AOC 1001, is in a Phase 1/2 clinical trial for myotonic dystrophy type 1, with other programs in the pipeline for rare skeletal muscle and cardiac diseases, showcasing a robust and diverse pipeline. (marketinference.com)
Avidity reported net losses of $212.2 million and $174.0 million for the years ended December 31, 2023, and 2022, respectively, with an accumulated deficit of $710.4 million as of June 30, 2024, raising concerns about ongoing profitability. (marketinference.com)
The company's research and development expenses increased significantly, reaching $95.6 million in Q4 2024 compared to $52.8 million in Q4 2023, which may impact short-term financial stability. (biospace.com)
Avidity's collaboration revenue decreased to $1.6 million in Q1 2025 from $3.5 million in Q1 2024, indicating potential challenges in partnership-driven income. (finviz.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
RNA Financial Performance
Revenues and expenses
RNA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avidity Biosciences stock?
Avidity Biosciences (RNA) has a market cap of $3.5B as of July 04, 2025.
What is the P/E ratio for Avidity Biosciences stock?
The price to earnings (P/E) ratio for Avidity Biosciences (RNA) stock is 0 as of July 04, 2025.
Does Avidity Biosciences stock pay dividends?
No, Avidity Biosciences (RNA) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Avidity Biosciences dividend payment date?
Avidity Biosciences (RNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Avidity Biosciences?
Avidity Biosciences (RNA) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.